UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): July 324, 2017

Interleukin Genetics, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware

(State or Other Jurisdiction of Incorporation)

001-32715		94-3123681
(Commission File Number)		(IRS Employer Identification No.)

135 Beaver Street Waltham, MA		02452
(Address of Principal Executive Offices)		(Zip Code)

(781) 398-0700

(Registrant’s Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

oIndicate ~~Soliciting~~by ~~material~~check ~~pursuant~~mark towhether the registrant is an emerging growth company as defined in Rule ~~14a~~405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-122 ~~under~~of the Securities Exchange Act ~~(17~~of ~~CFR~~1934 (§240.~~14a~~12b-122 of this chapter).

oEmerging ~~Pre-commencement~~growth ~~communications~~company ~~pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))~~¨

oIf ~~Pre-commencement~~an ~~communications~~emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to ~~Rule~~Section ~~13e-4~~13(ca) ~~under~~of the Exchange Act ~~(17 CFR 240~~.~~13e-4(c))~~ ¨

~~Indicate~~ITEM ~~by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230~~7.~~405)~~01 orRegulation ~~Rule~~FD ~~12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).~~Disclosure

~~Emerging~~To ~~growth~~the extent deemed necessary the information ~~company~~set ☐forth in Item 8.01 is hereby incorporated by reference into this Item 7.01.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

ITEM 2.02 Results of Operations and Financial Condition.

The information set forth in Item 8.01 is hereby incorporated by reference into this Item 2.02.

ITEM 2.05 Costs Associated with Exit or Disposal Activities.

The information set forth in Item 8.01 is hereby incorporated by reference into this Item 2.05.

ITEM 8.01

Other Events

On July 324, 2017, Interleukin Genetics, Inc. (the “Company”) issued a press release announcing: (i) that it is seeking ~~strategic~~relief ~~alternatives~~of its reporting obligations under Sections 12(g) and ~~restructuring~~15(d) of the Securities Act of 1934, (ii) several of members of its ~~operations.~~Board of Directors and Management team have resigned, and (iii) the adoption of a plan to wind-up and liquidate the Company.

A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

~~Item~~ITEM 9.01 Financial Statements and Exhibits.

(1) The ~~following~~disclosures ~~exhibit~~made isin Form 8-K filed ~~with~~July 3, 2017 are hereby incorporated by reference to this report:.

Exhibit Number	Description
99.1	Press Release dated July 3, 2017.

(2)

The following Exhibit is filed with this report.

Exhibit 99.1

Press release dated July 24, 2017

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	INTERLEUKIN GENETICS, INC.
Date: July 3, 2017		/s/ Mark B. Carbeau
Date: July 24, 2017	/s/ Barry Kallander
		Mark B. CarbeauChief Executive Officer
	Barry Kallander
	President

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press Release dated July 3, 2017.

Filing Compare · INTERLEUKIN GENETICS INC